Replies to post #278606 on Amarin Corp Plc (AMRN)

[Whalatane]

Bouf. Thx. Always appreciate your contributions to the board
Kiwi

[HinduKush]

Bouf

But this is not the ball game or a knock out, at best it is a helpful part of a broader case that needs to be made why Mori is at best weak evidence to support obviousness, far short of clear and convincing.

The case has been made and remade ad nauseam:
(1) Du totally misinterpreted what the data of Mori in Am J NUtrb2000 actually expressed, because of a naieve statistical interpretation promoted by the generics, that she bought hook line and sinker, that is invalid in any scientists view that studies it in detail...find one statistician that will say otherwise?
(2) Mori is irrelevant because it addresses the wrong population of ptaients that the MARINE patents address ie those with TG>500mg/dl where LDL lowering by any other method on omega 3 combination eg EPA + DHA or DHA would have increased the LDL as a consequence of the saturable mechanism in VLDL breakdown to IDL and then LDL
(3) Mori himself contradicted what his 2000 paper with an opposite result when he published a similar paper with Woodman 2 years later.(may or may not be admissible who knows?)
(3) Every paper between 2000-2008 including American Heart Asssociation state of the art guidelines in treating Hypertriglyceridemia, and POSA state of the art reviews/ meta analyses say unequivocally that all omega3 formulations will increase LDL as a consequence of how VLDL is metabolized.Where is the obviousness or the hint of a soupcon of evidence that EPA could do it without increasing LDL and lowering ApoB anywhere inthe litearture? As the Curfman article points out, MORI taught nothing and quite possibly taught the opposite of what Du thought it did...

If at the end of all that, CAFC Judges say "Oh well, a reasonable person could still have just inferred the opposite" then all I can say is the blind really are leading the mentally retarded in judging this case.